Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Conference News ACC 2022

Global STEMI Outcomes May Improve With Tracking, GHATI Hints

Shelley Wood

April 11, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

Todd Neale

April 08, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

Todd Neale

April 06, 2022

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

The PACMAN AMI Randomized Clinical Trial

Presenter: Lorenz Räber

April 04, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

Presentation ACC 2022

TRANSLATE-TIMI 70

Presenter: Brian Bergmark

April 04, 2022

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

Tailored Nutrition Advice at the Grocery Store Works: SuperWIN

Caitlin E. Cox

April 03, 2022

Advertisement

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Managing AF Patients Undergoing PCI—Some Lingering Questions

Global STEMI Outcomes May Improve With Tracking, GHATI Hints

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

The PACMAN AMI Randomized Clinical Trial

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

TRANSLATE-TIMI 70

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Tailored Nutrition Advice at the Grocery Store Works: SuperWIN

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content